Researchers use artificial intelligence to help tailor bowel cancer treatment
In a study by the S:CORT (Stratification in COloRecTal cancer) consortium, researchers led by Jens Rittscher (Dept. of Engineering Science, University of Oxford) and Viktor Koelzer (Dept. of Pathology and Molecular Pathology, University of Zurich) have used advanced machine learning approaches to study bowel cancer samples using digital images to establish the cancer subtype. This offers hope of more personalised treatment for bowel cancer patients.
Previous research has shown there are four distinct bowel cancer subtypes. Bowel cancers are grouped into subtypes by common patterns of gene expression – that is which genes are switched on or off. Clinicians hope to use this information in deciding which treatments are likely to work best. Currently, bowel cancer subtype is established through RNA analysis, which is not widely used due to high costs and the need for specialist knowledge to interpret the data.
The S:CORT team have trained a computational model to analyse digital images of bowel cancer samples, looking at how cells and structures in the sample are organised and working out the subtype. This is less expensive than sequencing and can use samples routinely taken in the clinic. In their new research paper, the team found the programme was able to accurately predict subtype from standard and readily available imaging data. They suggest this is a technique that could be used for other cancers and disease types in future.
“This research shows that, with the help of computer analysis, it is possible to detect complex biological patterns from the way cancer looks under the microscope using routine ways to prepare tissue slides. This has great potential for providing information on how the cancer will behave in the individual and use in the future to guide treatment decisions.” Tim Maughan, leader of the S:CORT consortium.
Dr Lisa Wilde, Director of Research and External Affairs, Bowel Cancer UK, comments: “This is an exciting step forward in the development of a clinical test that could help personalise treatment for bowel cancer patients. We know that the use of AI has great promise for improving the diagnosis and treatment of cancer. We are also delighted that this work is tackling research gaps identified in our Critical Gap in Colorectal Cancer Research project.”